Cellino, a Cambridge, Mass.-based personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, closed a $16M seed financing round.
The round was co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC.
The company intends to use the funds to automate and scale its AI-based personalized tissue and cell platform.
Led by Nabiha Saklayen, Ph.D., CEO & Co-Founder, Cellino is developing an automated process to generate autologous induced pluripotent stem cells (iPSCs) at scale. The proprietary platform converges technologies across optics, biology, and machine learning to engineer high functionality cells. The platform automates stem cell production using image-guided machine learning, single-cell laser processing, and robotics. By standardizing manufacturing in a closed format, Cellino creates an opportunity to scale from pre-clinical process development to commercial-scale manufacturing for autologous iPSC-based therapies.